Global Cell & Gene Therapy Manufacturing Services Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

Cell & gene therapy manufacturing services include comprehensive and seamless manufacturing and quality-testing services for cellular and gene therapy products. The service provider helps biotechnology & pharmaceutical companies and research groups boost translational and clinical discoveries and foster an environment of collaboration and innovation. Cell therapy manufacturing services include allogeneic, autologous, and viral vectors, while gene therapy manufacturing services non-viral vectors, oligonucleotides, and viral vectors. Cell & gene therapy manufacturing services provide flexible and pioneering tools to simplify workflow, innovation, scalability, customization, consistency, reproducibility, reducing risk, and navigate at every step of the manufacturing process.

Market Dynamics:

Factors such as the high prevalence of cancer and chronic diseases, increasing spending in pharmaceutical & biological research, and increasing collaboration among companies and CDMOs are primarily driving the growth of the global cell & gene therapy manufacturing services market. Cell and gene therapies offer potential promise to treat and relieve life-threatening diseases. Pharmaceutical companies are massively investing in the development of new drugs and therapies. Pharmaceutical companies are more usually outsource their research CDMOs or CROs to focus on core activities. Moreover, Pharmaceutical companies find it challenging to do R&D with high quality and efficiency. Outsourcing stands out as the best approach to them. However, the high operational costs concerned with cell & gene therapy manufacturing are likely to restrain market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell & gene therapy manufacturing services. The growth and trends of cell & gene therapy manufacturing services industry provide a holistic approach to this study.

Market Segmentation:

This section of the cell & gene therapy manufacturing services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Cell Therapy (Allogeneic, Autologous, Viral Vector)
Gene Therapy (Non-viral Vector, Viral Vector)

By Indication

Oncology Diseases
Cardiovascular Diseases
Orthopedic Diseases
Ophthalmology Diseases
Central Nervous System Disorders
Infectious Diseases
Other

By Application

Clinical Manufacturing
Commercial Manufacturing

By End User

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Other End User

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Manufacturing Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell & gene therapy manufacturing services market include Lonza (Switzerland), Catalent Inc. (US), Thermo Fisher Scientific Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Cell and Gene Therapy Catapult (UK), Genezen (US), FUJIFILM Holdings Corporation (Japan), Nikon Corporation (Japan), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS Pharma (Germany), FinVector (Finland), ABL Inc. (US), Resilience (US), BioCentriq (US), Porton Advanced Solutions (China), Andelyn Biosciences (US), Forge Biologics (US), Vibalogics (US), Anemocyte Srl (Italy), ElevateBio (US) This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215654

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELL & GENE THERAPY MANUFACTURING SERVICES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Type
- 3.7.2 By Indication
- 3.7.3 By Application
- 3.7.4 By End User
- 3.7.5 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Cell Therapy Market by Regions
6.5 Gene Therapy Market by Regions

7 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology Diseases Market by Regions
7.5 Cardiovascular Diseases Market by Regions
7.6 Orthopedic Diseases Market by Regions
7.7 Ophthalmology Diseases Market by Regions
7.8 Central Nervous System Disorders Market by Regions
7.9 Infectious Diseases Market by Regions
7.10. Other Market by Regions

8 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY APPLICATION

8.1 Overview by Application
8.2 Historical and Forecast Data
8.3 Analysis by Application
8.4 Clinical Manufacturing Market by Regions
8.5 Commercial Manufacturing Market by Regions

9 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY END USER

9.1 Overview by End User
9.2 Historical and Forecast Data
9.3 Analysis by End User
9.4 Pharmaceutical & Biotechnology Companies Market by Regions
9.5 Academic & Research Institutes Market by Regions
9.6 Other End User Market by Regions

10 . GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America
- 10.3.1. Overview, Historic and Forecast Data
- 10.3.2. North America By Segment
- 10.3.3. North America By Country
- 10.3.4. United State
- 10.3.5. Canada
- 10.3.6. Mexico
10.4. Europe
- 10.4.1. Overview, Historic and Forecast Data
- 10.4.2. Europe by Segment
- 10.4.3. Europe by Country
- 10.4.4. United Kingdom
- 10.4.5. France
- 10.4.6. Germany
- 10.4.7. Italy
- 10.4.8. Russia
- 10.4.9. Rest Of Europe
10.5. Asia Pacific
- 10.5.1. Overview, Historic and Forecast Data
- 10.5.2. Asia Pacific by Segment
- 10.5.3. Asia Pacific by Country
- 10.5.4. China
- 10.5.5. India
- 10.5.6. Japan
- 10.5.7. South Korea
- 10.5.8. Australia
- 10.5.9. Rest Of Asia Pacific
10.6. Latin America
- 10.6.1. Overview, Historic and Forecast Data
- 10.6.2. Latin America by Segment
- 10.6.3. Latin America by Country
- 10.6.4. Brazil
- 10.6.5. Argentina
- 10.6.6. Peru
- 10.6.7. Chile
- 10.6.8. Rest of Latin America
10.7. Middle East & Africa
- 10.7.1. Overview, Historic and Forecast Data
- 10.7.2. Middle East & Africa by Segment
- 10.7.3. Middle East & Africa by Country
- 10.7.4. Saudi Arabia
- 10.7.5. UAE
- 10.7.6. Israel
- 10.7.7. South Africa
- 10.7.8. Rest Of Middle East And Africa

11 . COMPETITIVE LANDSCAPE OF THE CELL & GENE THERAPY MANUFACTURING SERVICES COMPANIES

11.1. Cell & Gene Therapy Manufacturing Services Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF CELL & GENE THERAPY MANUFACTURING SERVICES INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Lonza (Switzerland)
- 12.3.1. Company Overview
- 12.3.2. Financials
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Catalent Inc. (US)
- 12.4.1. Company Overview
- 12.4.2. Financials
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Thermo Fisher Scientific Inc. (US)
- 12.5.1. Company Overview
- 12.5.2. Financials
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Charles River Laboratories (US)
- 12.6.1. Company Overview
- 12.6.2. Financials
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. WuXi AppTec (China)
- 12.7.1. Company Overview
- 12.7.2. Financials
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Merck KGaA (Germany)
- 12.8.1. Company Overview
- 12.8.2. Financials
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Takara Bio Inc. (Japan)
- 12.9.1. Company Overview
- 12.9.2. Financials
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Oxford Biomedica (UK)
- 12.10.1. Company Overview
- 12.10.2. Financials
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Cell and Gene Therapy Catapult (UK)
- 12.11.1. Company Overview
- 12.11.2. Financials
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Genezen (US)
- 12.12.1. Company Overview
- 12.12.2. Financials
- 12.12.3. Products
- 12.12.4. Recent Developments
12.13. FUJIFILM Holdings Corporation (Japan)
- 12.13.1. Company Overview
- 12.13.2. Financials
- 12.13.3. Products
- 12.13.4. Recent Developments
12.14. Nikon Corporation (Japan)
- 12.14.1. Company Overview
- 12.14.2. Financials
- 12.14.3. Products
- 12.14.4. Recent Developments
12.15. The Discovery Labs LLC (US)
- 12.15.1. Company Overview
- 12.15.2. Financials
- 12.15.3. Products
- 12.15.4. Recent Developments
12.16. RoslinCT (Scotland)
- 12.16.1. Company Overview
- 12.16.2. Financials
- 12.16.3. Products
- 12.16.4. Recent Developments
12.17. JRS Pharma (Germany)
- 12.17.1. Company Overview
- 12.17.2. Financials
- 12.17.3. Products
- 12.17.4. Recent Developments
12.18. FinVector (Finland)
- 12.18.1. Company Overview
- 12.18.2. Financials
- 12.18.3. Products
- 12.18.4. Recent Developments
12.19. ABL Inc. (US)
- 12.19.1. Company Overview
- 12.19.2. Financials
- 12.19.3. Products
- 12.19.4. Recent Developments
12.20. Resilience (US)
- 12.20.1. Company Overview
- 12.20.2. Financials
- 12.20.3. Products
- 12.20.4. Recent Developments
12.21. BioCentriq (US)
- 12.21.1. Company Overview
- 12.21.2. Financials
- 12.21.3. Products
- 12.21.4. Recent Developments
12.22. Porton Advanced Solutions (China)
- 12.22.1. Company Overview
- 12.22.2. Financials
- 12.22.3. Products
- 12.22.4. Recent Developments
12.23. Andelyn Biosciences (US)
- 12.23.1. Company Overview
- 12.23.2. Financials
- 12.23.3. Products
- 12.23.4. Recent Developments
12.24. Forge Biologics (US)
- 12.24.1. Company Overview
- 12.24.2. Financials
- 12.24.3. Products
- 12.24.4. Recent Developments
12.25. Vibalogics (US)
- 12.25.1. Company Overview
- 12.25.2. Financials
- 12.25.3. Products
- 12.25.4. Recent Developments
12.26. Anemocyte Srl (Italy)
- 12.26.1. Company Overview
- 12.26.2. Financials
- 12.26.3. Products
- 12.26.4. Recent Developments
12.27. ElevateBio (US)
- 12.27.1. Company Overview
- 12.27.2. Financials
- 12.27.3. Products
- 12.27.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies